Cure Pharmaceutical Holding Stock News

Soligenix (NASDAQ:SNGX) and CURE Pharmaceutical (OTCMKTS:CURR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. Profitability This table compares Soligenix and CURE Pharmaceuticals net margins, return on equity and return on []

HEXO Reports First Quarter 2022 Results and Launches New Strategic Plan, “The Path Forward” to Solidify its Position as Canada’s Leading Cannabis Company HEXO Corp (TSX: HEXO; NASDAQ: HEXO) (“HEXO” or the “Company”), a leading producer of high-quality cannabis products, today reported its financial results for the fiscal quarter ended October 31, 2021 (Q1’22), and announced “The Path Forward”, a new strategic plan to solidify itself as Canada’s leading cannabis company and position it to capitalize on international opportunities. The plan utilizes HEXO’s current assets, including its recent acquisitions and unique capabilities to drive accelerated growth and become cash flow positive within the next four quarters. This plan is underpinned by actions to strengthen its balance sheet, its executive team and its corporate governance. Q1 2022 Highlights Total net revenue increased 29% to $50.2 million from $38.7 million in Q4’21, and up 70% from the comparative quarter of fiscal 2021. The Company closed its acquisitions of Redecan and 48North which contributed net revenues of $13.5 Million and $1.1 Million respectively during the two months ended October 31, 2022.

CURE Pharmaceutical (OTCMKTS: CURR) is one of 904 publicly-traded companies in the Pharmaceutical preparations industry, but how does it weigh in compared to its competitors? We will compare CURE Pharmaceutical to similar companies based on the strength of its profitability, analyst recommendations, risk, dividends, valuation, institutional ownership and earnings. Institutional and Insider Ownership 0.2% of []

CURE Pharmaceutical (OTCMKTS: CURR) is one of 901 publicly-traded companies in the Pharmaceutical preparations industry, but how does it compare to its rivals? We will compare CURE Pharmaceutical to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership. Institutional and Insider Ownership 0.2% of CURE Pharmaceutical []

Global Oral Disintegrating Film Sales Market Report 2021 The Oral Disintegrating Film Market Report 2021-2027 provides global market size, regional and national level market size, market segment growth, market share, competitive landscape, sales analysis, influence of domestic and global market participants,

CURE Pharmaceutical (OTCMKTS: CURR) is one of 896 public companies in the Pharmaceutical preparations industry, but how does it contrast to its competitors? We will compare CURE Pharmaceutical to related businesses based on the strength of its valuation, risk, earnings, institutional ownership, analyst recommendations, dividends and profitability. Valuation & Earnings This table compares CURE Pharmaceutical [] The post CURE Pharmaceutical (CURR) versus The Competition Financial Contrast appeared first on ETF Daily News .

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the 331 patent) is set to issue on November 23, 2021. The 331 patent, entitled Oral Soluble Film Containing Sildenafil Citrate, cov

Pharmaceutical company CURE Pharmaceutical Holding Corp. (OTC:CURR) announced earnings results on Tuesday for the quarter ended June 30, revealing revenue of $2.1 million. That's a year-over-year in

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and heal

CURE Pharmaceutical (OTC:CURR) has signed an agreement with Biopharmaceutical Research Company (BRC) to produce federally compliant medical cannabis, CBD and THC products. BRC will provide the cannabi

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an op

LOS ANGELES--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today th

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today